A different diligence perspective
Challenge assumptions with independent biological risk measurement, not automated investment advice.
MBRSBIOCOMPUTED DRUG-DEVELOPMENT INTELLIGENCE
Browse and generate your own surfaced drug-development risk portfolios.
Understand asset–indication risk through a common biological lens. Discover ecosystem leaders, emerging competitors, and the differentiation that may shape development.
OUR PERSPECTIVE
A company's core value is its asset. An asset's core value is its biology.
Our core value is surfacing that biology—and finding its differentiation. MBRS computes mechanistic and biological relationships through a neural framework; its core risk scoring is not generated by a large language model. MBRS provides an independent biological perspective on asset–indication fit and competitive development risk.
Program and competitor context
Compare the biological positioning of an asset with competitors in its indication.
Investigate further
Identify questions, alternative indications and potential combinations for deeper research.
YOUR WORKSPACE
Submit one program. Understand the ecosystem around it.
With an approved account, submit a patent, deck, report or other relevant development intelligence. MBRS is designed to connect it to biological parameters and a comparative ecosystem, with dated, traceable Analyst reports and primary-asset portfolio packets after processing.
Use MBRS as a systematic “other voice” alongside your scientific, clinical, commercial, and regulatory diligence. Ecosystems change; versioned analyses make those changes visible rather than erasing prior conclusions.